Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 395 0.09%
25 Nov 12:37 p.m.
biocon.com BSE: 532523 NSE: BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Business Segments
1) Biosimilars (58% in FY25 vs 50% in FY23): [1] [2] Biocon Biologics develops and markets a range of 20 biosimilars including insulins, monoclonal antibodies, and conjugated recombinant proteins across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. [3] It is one of the top 5 global players in biosimilars and among the top 3 in insulins. It ranks in the top 15 companies worldwide for biomanufacturing capacity and has a presence in 120+ countries, including the U.S., Europe, and emerging markets. Its product portfolio includes 10 approved biosimilars and 10 under development. [4]

The segment revenue grew by 2% YoY in FY25, driven by market share gains in the U.S. and key tender wins in the Emerging Markets. [5]

Website BSE NSE
  • Market Cap ₹ 52,810 Cr.
  • Current Price ₹ 395
  • High / Low ₹ 425 / 291
  • Stock P/E 111
  • Book Value ₹ 200
  • Dividend Yield 0.13 %
  • ROCE 6.25 %
  • ROE 4.76 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • Company has low interest coverage ratio.
  • Company has a low return on equity of 4.94% over last 3 years.
  • Company might be capitalizing the interest cost
  • Promoter holding has decreased over last 3 years: -6.19%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
2,320 2,941 3,774 3,423 3,462 3,954 3,917 3,433 3,590 3,821 4,417 3,942 4,296
1,877 2,352 2,817 2,741 2,745 3,051 3,004 2,812 2,905 3,070 3,339 3,193 3,460
Operating Profit 442 589 957 681 717 903 913 620 685 752 1,078 749 835
OPM % 19% 20% 25% 20% 21% 23% 23% 18% 19% 20% 24% 19% 19%
48 -193 152 94 134 587 40 1,166 58 53 57 80 81
Interest 30 120 249 233 248 267 227 236 226 223 212 277 272
Depreciation 231 301 364 358 389 414 407 405 420 425 436 455 473
Profit before tax 229 -26 497 184 214 808 319 1,146 98 156 487 97 171
Tax % 64% -19% 17% 19% 19% 7% 30% 25% 72% 48% 6% 8% 22%
82 -21 414 149 173 753 223 862 27 81 459 89 133
EPS in Rs 0.39 -0.35 2.61 0.84 1.05 5.50 1.13 5.49 -0.13 0.21 2.87 0.23 0.63
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
2,877 3,090 3,347 3,891 4,123 5,514 6,367 7,143 8,184 11,174 14,756 15,262 16,476
2,190 2,394 2,957 2,912 3,294 4,121 4,792 5,562 6,391 8,762 11,540 12,008 13,062
Operating Profit 687 696 390 980 829 1,394 1,575 1,581 1,793 2,412 3,216 3,254 3,414
OPM % 24% 23% 12% 25% 20% 25% 25% 22% 22% 22% 22% 21% 21%
56 158 639 173 228 340 228 260 72 18 853 1,217 271
Interest 2 9 29 26 62 71 65 58 68 419 974 897 985
Depreciation 204 221 249 277 385 448 552 715 814 1,113 1,569 1,687 1,790
Profit before tax 538 624 751 850 610 1,215 1,186 1,068 983 897 1,525 1,887 911
Tax % 20% 15% 19% 19% 26% 17% 27% 21% 22% 28% 15% 24%
431 528 609 688 453 1,003 871 846 772 643 1,298 1,429 762
EPS in Rs 3.45 4.14 4.59 5.10 3.10 7.54 6.24 6.17 5.40 3.85 8.52 8.44 3.94
Dividend Payout % 24% 20% 18% 10% 16% 7% 0% 0% 9% 39% 6% 6%
Compounded Sales Growth
10 Years: 17%
5 Years: 19%
3 Years: 23%
TTM: 11%
Compounded Profit Growth
10 Years: 9%
5 Years: 7%
3 Years: 10%
TTM: -66%
Stock Price CAGR
10 Years: 18%
5 Years: -1%
3 Years: 12%
1 Year: 18%
Return on Equity
10 Years: 7%
5 Years: 6%
3 Years: 5%
Last Year: 5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 100 100 100 100 300 300 600 600 600 600 600 600 668
Reserves 2,927 3,171 3,934 4,738 4,881 5,798 6,106 7,027 7,832 17,267 19,183 21,044 26,135
864 1,117 2,478 2,302 2,264 2,422 2,715 4,481 5,147 18,019 16,277 18,362 16,536
1,860 1,988 1,947 2,254 2,545 3,672 4,993 6,382 6,763 15,856 19,693 18,534 19,421
Total Liabilities 5,751 6,375 8,458 9,394 9,990 12,192 14,414 18,490 20,342 51,742 55,753 58,540 62,760
1,525 1,630 1,748 3,626 3,700 4,471 5,971 6,364 6,569 29,468 30,644 31,963 37,262
CWIP 1,206 1,677 2,240 839 1,303 1,899 2,196 2,800 4,110 7,317 7,993 8,508 4,651
Investments 765 230 902 1,253 675 1,012 966 1,952 1,588 2,069 1,000 1,127 2,333
2,255 2,839 3,569 3,676 4,312 4,811 5,281 7,374 8,074 12,888 16,117 16,941 18,513
Total Assets 5,751 6,375 8,458 9,394 9,990 12,192 14,414 18,490 20,342 51,742 55,753 58,540 62,760

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
561 211 371 640 662 1,155 1,283 1,160 1,177 1,852 2,954 4,061
-904 -491 -1,138 -510 -684 -703 -1,505 -3,651 -1,662 -14,260 -1,002 -203
426 186 1,068 -178 -240 -242 388 2,564 242 13,049 -2,333 -1,854
Net Cash Flow 83 -94 300 -47 -261 210 165 72 -243 641 -380 2,004

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 76 91 78 83 94 86 70 77 92 117 154 131
Inventory Days 116 132 153 160 161 199 255 304 309 423 368 346
Days Payable 107 125 172 187 224 231 236 246 216 383 467 460
Cash Conversion Cycle 85 98 59 57 31 53 90 134 184 157 55 18
Working Capital Days -31 -19 -12 24 6 -2 -31 8 71 3 -68 -63
ROCE % 15% 12% 9% 12% 8% 13% 12% 10% 9% 6% 6% 6%

Shareholding Pattern

Numbers in percentages

1 Recently
Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 54.45% 54.45%
14.42% 10.20% 9.52% 7.97% 6.55% 5.63% 5.90% 5.93% 5.66% 5.67% 6.04% 6.61%
8.63% 11.89% 12.59% 14.08% 14.51% 13.69% 14.29% 14.44% 15.36% 15.73% 22.83% 22.06%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.03%
15.74% 16.70% 16.77% 16.92% 17.96% 19.74% 18.90% 18.74% 18.11% 17.77% 16.51% 16.70%
0.58% 0.55% 0.49% 0.39% 0.33% 0.32% 0.28% 0.25% 0.22% 0.21% 0.18% 0.14%
No. of Shareholders 3,91,3824,11,0864,12,4414,15,0464,34,3394,70,2614,43,5134,39,5034,27,7054,24,2974,28,1314,13,191

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls